Skip to NavigationSkip to content

Pharmafile - Medical Communications News

Eisai has revealed that its multireceptor Tyrosine Kinase Inhibitor Lenvima (lenvatinib) has been recommended by NICE, meaning it can now be used...
Check out this week’s top ten most popular stories on Pharmafile.com!
Britain’s cost effectiveness body the National Institute of Health and Care Excellence (NICE) has chosen not to recommend AstraZeneca’s Olaparib...
The NHS in England is now spending over £1billion a year on diabetes prescriptions, almost doubling in the last decade, according to NHS Digital.
The state of Alabama’s biggest insurer Blue Cross and Blue Shield will no long cover opioid painkiller OxyContin. The decision has come in response...
With news on Trump's latest attempts to tackle the US opioid and pricing crises, Brexit warnings for medicine availability and research, and features...
Researchers have found that GlaxoSmithKline’s ezogabine (Potiga), approved by the FDA in 2011 as an anti-seizure therapy, could have applications...
Check out the Top Ten most popular articles on Pharmafile.com this week!
Alkermes has been knocked back with the disappointing, though not entirely unexpected, news that the FDA-appointed Psychopharmacologic Drugs...
Danish multinational Novo Nordisk has said that they will have cut 1,300 employees by the end of 2018. The decision has come partly in response to...
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches